TNFRSF6B and glioblastoma: Recently, DcR3 has attracted extensive attention because its aberrant expression has been detected in various types of malignant tumors, especially hepatocellular carcinoma [12], pancreatic carcinoma [27], nasopharyngeal carcinoma [9], ovarian cancer [28], gastric carcinoma [29] and glioblastoma [30].